Quality of life in alopecia areata: a study of 60 cases
M Dubois et al.
Quality of Life in Alopecia Areata
Hegemann L, Forstinger C, Partsch B et al. (1995)
Nowak A, Klimowicz A (1990) 2-Stage penetra-
Roos K, Brorson JE (1990) oncentration of
Microdialysis in cutaneous pharmacology—
tion of a single oral dose of sulfadimethoxine
phenoxymethylpenicillin in tonsillar tissue.
kinetic-analysis of transdermally delivered
into skin blister fluid. Eur J Clin Pharmacol
nicotine. J Investig Dermatol 104:839–43
Jynge P, Skjetne T, Gribbestad I et al. (1990)
Pershing LK, Nelson JL, Corlett JL et al.
et al. (1999) Bioavailability of clobetasol
propionate—quantification of drug concen-
fluorine magnetic-resonance spectroscopy—
trations in the stratum corneum by dermato-
a study of liver and muscle disposition of
fleroxacin in humans. Clin Pharmacol Ther
Quality of Life in Alopecia Areata: A Study of 60 Cases
Journal of Investigative Dermatology (2010) 130, 2830–2833; published online 19 August 2010
skin disorders’’-specific Qol instru-
affected and symptoms the least one.
Qol for almost all the SF36 dimensions.
leisure activity, daily life, and physical
adherence to the Helsinki guidelines.
pathic urticaria, and atopic dermatitispatients; (ii) being less bothered totreatment-induced
Abbreviations: AA, alopecia areata; Qol, quality of life; SF36, short form 36
2830 Journal of Investigative Dermatology (2010), Volume 130
Table 1. Quality-of-life indicative comparisons between AA patients and other dermatological conditions, andFrench age- and sex-matched controls1
37.4±24.7 o0.001 23.8±21.8 o0.001 34.2±24.6 o0.001
0.145 36.2±20.4 o0.001 35.5±21.3 o0.001
49.3±25.2 o0.001 50.3±25.5 o0.001 50.1±25.5 o0.001
47.2±29.3 o0.001 36.7±28.1 o0.001 46.7±27.9 o0.001
Treatment restrictions 30.3±30.2 35.8±34.0
44.4±28.2 o0.001 61.4±23.7 o0.001 69.8±21.3 o0.001
Abbreviations: AA, alopecia areata; AD, atopic dermatitis; CU, chronic urticaria; HS, hidradenitis suppurativa; NF1, neurofibromatosis type 1; PSO,psoriasis; SF36, short form 36.
2SF36, 36 items, eight dimensions (range (0–100), 0 lowest and 100 highest level of Qol;
3VQ-Dermato, 28 items, seven domains and one overall score (range (0–100), 0 highest and 100 lowest level of Qol;
4Skindex, 29 items, three domains (range (0–100), 0 highest and 100 lowest level of Qol; Bold values Po0.05.
Table 2. Associations between VQ-Dermato dimension scores and global score, and sociodemographic/clinicalcharacteristics in 60 alopecia areata (AA) patients
M Dubois et al.
Quality of Life in Alopecia Areata
1Mean ± SD, P: P-value Mann–Whitney test.
2Spearman’s correlation coefficient, P: P-value Spearman’s test.
3Course of the disease was defined as ‘‘unstable’’ if there was alternation of worsening and improvement phases in the last 2 years, and ‘‘stable’’ otherwise.
4Severity 1: visual analog scale by reference to the cases of AA seen in daily practice; 0 ‘‘patient among the least affected’’ and 100 ‘‘patient among the mostaffected’’.
5Severity 2: visual analog scale by reference to the cases of all skin disorders seen in daily practice; 0 ‘‘patient among the least affected’’ and 100 ‘‘patientamong the most affected’’.
Bold values: Po0.05.
2832 Journal of Investigative Dermatology (2010), Volume 130
Cash TF (1999) The psychosocial consequences of
androgenetic alopecia: a review of the research
Chren MM, Lasek RJ, Flocke SA et al. (1997)
Improved discriminative and evaluative cap-ability of a refined version of Skindex, a
quality-of-life instrument for patients with
skin diseases. Arch Dermatol 133:1433–40
Chren MM, Lasek RJ, Quinn LM et al. (1996)
clinical parameters (data not shown).
patients with skin disease: reliability, validity,and responsiveness. J Invest Dermatol 107:
atically search for other health disorders
Coste J (2001) Medical Outcome Study Short Form
Firooz A, Firoozabadi MR, Ghazisaidi B et al.
(2005) Concepts of patients with alopecia
areata about their disease. BMC Dermatol5:1
Grob JJ, Auquier P, Dreyfus I et al. (2009) How to
prescribe antihistamines for chronic idio-
pathic urticaria: desloratadine daily versus
PRN and quality of life. Allergy 64:605–12
and also mental health and social life. It
Grob JJ, Auquier P, Martin S et al. (1999)
Development and validation of a quality oflife measurement for chronic skin disorders
in french: VQ-Dermato.The Reseau d’ Epi-
Grob JJ, Revuz J, Ortonne JP et al. (2005)
Comparative study of the impact of chronicurticaria, psoriasis and atopic dermatitis on
Gulec AT, Tanriverdi N, Duru C et al. (2004) The
role of psychological factors in alopecia
The authors state no conflict of interest.
areata and the impact of the disease on thequality of life. Int J Dermatol 43:352–6
Leplege A, Ecosse E, Pouchot J et al. (2001) MOS
ACKNOWLEDGMENTSThis work was supported by institutional grants
SF36 Questionnaire. Manual and Guidelines
from the PHRC 2005 (Program Hospitalier Recherche
for Scores’ Interpretation. Vernouillet: Estem,
Leplege A, Ecosse E, Verdier A et al. (1998)
tion, cultural adaptation and preliminary
psychometric evaluation. J Clin Epidemiol
Leplege A, Ecosse E, Zeller J et al. (2003)
France). Adaptation and assessment of psycho-
1Department of Dermatology, Sainte-Marguerite
Hospital, Marseille, France; 2Department of
Wolkenstein P, Loundou A, Barrau K et al. (2007)
Clinical Research, Assistance Publique des
Quality of life impairment in hidradenitis
Hoˆpitaux de Marseille, Marseille, France;
suppurativa: a study of 61 cases. J Am Acad
EA3279 ‘‘Self-Perceived Health Assessment’’
Research Unit and Department of Public Health,
Wolkenstein P, Zeller J, Revuz J et al. (2001)
Nord Hospital, Universite´ de la Me´diterrane´e,
Quality-of-life impairment in neurofibroma-
tosis type 1: a cross-sectional study of 128
Miércoles 12 de Octubre de 2011 Santoral Nuestra Señora del Pilar, santos Eustaquio y Maximiliano Día de la Hispanidad El Sol La Luna Sale a las 06:22 (gmt) Sale a las 17:34 (gmt) Se pone a las 17:40 (gmt) Se pone a las 06:44 (gmt) Horóscopo del día: GÉMINIS Luna l ena en Aries. Aunque estemos en día de trabajo tú vas a tener el espírit
Internally Funded Research Hammond Awards January 1, 2012 – December 31, 2012 Project Title Safety vs. Success: Perceptions for IVF outcomes from double embryo transfer Tensile strength of 2nd-generation permanent surgical mesh for pelvic organ prolapse: a cadaver study Innovative Method to Personalize Overactive Bladder Therapy (IMPROVE)” Determination of the cost of travel fo